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Summary:
Up to a third of autologous transplantation candidates fail to mobilize hematopoietic progenitors into the peripheral blood with chemotherapy and/or growth factor treatment, thus requiring innovative mobilization strategies. In total, 20 cancer patients unable to provide adequate PBPC products after a previous mobilization attempt were treated with ancestim (20 lg/kg/day s.c.) and filgrastim (10 lg/kg/day s.c.). In 16 patients, the pre-study mobilization was with filgrastim alone. Eight patients underwent single large volume leukapheresis (LVL) and 12 multiple standard volume leukaphereses (SVL) in both mobilizations. Pairwise comparison of peripheral blood CD34 þ cell concentrations on the day of first leukapheresis failed to document synergism -median CD34 þ /ll of 3.2 (o0.1 to 15.4) and 4.5 (1-28.56 ) for the pre-study and on-study mobilizations (P ¼ 0.79, sign test), and 4.2 (o0.1-15.4) and 5 (1-28.56), respectively, for the 16 patients previously mobilized with filgrastim alone (P ¼ 1, sign test). The number of CD34 þ cells/kg collected per unit of blood volume (BV) processed was similar in both mobilizations -median 0.1 Â 10 6 /kg/BV and 0.09 Â 10 6 /kg/BV, respectively (P ¼ 1, sign test). In this phase II study, the combination of ancestim and filgrastim did not allow adequate PBPC mobilization and collection in patients with a previous suboptimal PBPC collection. High-dose chemoradiotherapy, with autologous or allogeneic hematopoietic support, is increasingly used to treat hematological malignancies and selected solid tumors. [1] [2] [3] In the last decade, peripheral blood has replaced bone marrow as the preferred source of hematopoietic progenitors to achieve hematological reconstitution. Peripheral blood progenitor cell (PBPC) transplants were shown to result in a faster hematological reconstitution when compared to bone marrow infusions, in randomized and nonrandomized studies. [4] [5] [6] [7] PBPC harvesting has the additional advantage of being performed in the outpatient setting, avoiding general anesthesia. However, in the majority of patients multiple leukaphereses are needed to collect a PBPC product. [7] [8] [9] To overcome the inconvenience and cost of multiple procedures, large volume leukaphereses (LVL), defined as the processing of more than three blood volumes (BVs) or 15 l of blood in a single session, have been used as a way of processing a high number of patients' BVs in a single session. [10] [11] [12] [13] [14] LVL can also recruit PBPC into the circulatory compartment, allowing the continuous harvest of large numbers of progenitors throughout the procedure. [10] [11] [12] 14 Similar recruitment of PBPC has been reported by some 15 but not others 16 with standard volume leukapheresis (SVL). The group in Lisboa 10 and others [11] [12] [13] [14] have shown that LVL is safe and at least as efficient as SVL for PBPC harvesting, allowing the collection of an adequate PBPC product in the majority of cancer patients in a single session.
Regardless of the type of apheresis procedure used, hematopoietic progenitors need to be mobilized into the peripheral blood by the administration of chemotherapy, hematopoietic growth factors (mostly G-CSF) or their combination. 4, 5, 17 Such mobilization increases the concentration of hematopoietic progenitors in the circulation, thus reducing the number of leukaphereses required to collect a PBPC product capable of hematopoietic reconstitution. Prior therapy, bone marrow involvement by the tumor and cancer diagnosis can influence the ability to mobilize adequate numbers of PBPC. [18] [19] [20] However, it is difficult to predict CD34 þ cell yields in individual patients and even healthy donors exhibit unexpectedly variable ability to mobilize PBPC. 21 The proportion of patients who fail to mobilize enough progenitors for transplantation (less than 1-2 Â 10 6 CD34 þ cells/kg, according to most authors) varies between 10 and 30% in published series. [22] [23] [24] For these 'poor mobilizers', the ideal mobilization regimen remains to be defined. Although there is some evidence that chemotherapy combined with growth factors allows the harvesting of higher numbers of progenitors than either strategy alone, 17 other investigators did not find significant differences between these approaches. 25, 26 While 2 Â 10 6 CD34 þ cells/kg are enough to ensure a rapid neutrophil recovery, it has been shown that a minimum of 5 Â 10 6 CD34 þ cells/kg are required for optimal platelet recovery. 24, 26 Thus, we chose the eligibility cut-off of 2.5 Â 10 6 CD34 þ cells/ kg aiming to collect an ideal overall product of 5 Â 10 6
CD34
þ cells/kg after the second 'on-study' mobilization attempt.
Ancestim (recombinant human stem cell factor, SCF) is a growth factor for primitive hematopoietic stem cells that can mobilize PBPC into peripheral blood in animals and has been shown to synergize with filgrastim (G-CSF) for PBPC mobilization in cancer patients. [27] [28] [29] [30] [31] In randomized studies comparing the combination of ancestim and filgrastim with either factor alone, with or without chemotherapy, the addition of SCF to the mobilization regimen (filgrastim or chemotherapy with filgrastim) decreased the number of leukaphereses required to achieve the target number of 5 Â 10 6 CD34 þ cells/kg and significantly increased the number of CD34 þ cells harvested. 29, 30 These observations were confirmed in a cohort of heavily pretreated patients with Hodgkin's disease and non-Hodgkin's lymphoma. 31 However, it is not known if combination regimens with filgrastim and ancestim can allow the harvest of adequate numbers of PBPC in 'poor mobilizers'.
In this multicenter, nonrandomized study, we used a combination of filgrastim and ancestim as the salvage mobilization regimen for patients who had failed to collect at least 2.5 Â 10 6 CD34 þ cells/kg in a previous PBPC mobilization attempt. Since the patients were to have a second PBPC mobilization attempt, the cut-off of 2.5 Â 10 6
þ cells/kg was chosen because it is half the number of hematopoietic progenitors shown to be necessary for optimal platelet recovery. [24] [25] [26] [27] [28] [29] [30] [31] We aimed to compare the efficacy of the PBPC mobilization regimen of filgrastim and ancestim with that of standard regimens in this patient population. PBPC were harvested by LVL or SVL according to the standard practice at either transplantation center. CD34 þ cells were measured in peripheral blood before mobilization and before harvesting, as well as in PBPC products. To adjust for differences in patients' peripheral blood concentration of CD34 þ cells, as well as in the number of processed BVs per leukapheresis session, we compared the number of circulating CD34 þ cells collected per unit of processed BV in the pre-study ('failed') mobilization attempt with the ancestim plus filgrastim mobilization.
Patients and methods

Patient eligibility
Patients older than 18 years with cancer, other than leukemia, who were candidates for autologous hematopoietic stem cell transplantation and in whom less than 2.5 Â 10 6 CD34 þ cells/kg were collected in a previous single LVL or a maximum of three SVL, performed after standard mobilization strategies at the Instituto Portugueˆs de Oncologia in Lisboa and in Porto (Portugal), were eligible. Patients were ineligible if they had an ECOG performance status X3, prior treatment with high-dose therapy and hematopoietic stem cell support, an absolute neutrophil count (ANC) o1.5 Â 10 9 /l or platelet count o100 Â 10 9 /l, serum creatinine 42.5 mg/dl and bilirubin, aspartate-amino transferase (AST) and alanine-amino transferase (ALT) more than twice the upper limit of normal. Other exclusion criteria included clinical and microbiological evidence of infection; clinically significant nonmalignant disease; and pregnancy, breast feeding or refusal to use adequate contraceptive measures in patients of childbearing potential.
Because of potential allergic reactions associated with ancestim, any history of asthma (within the preceding 10 years), anaphylactic events, angioedema or recurrent urticaria as well as known sensitivity to Escherichia coliderived products, positive allergy tests to insect venoms, concurrent use of beta-adrenergic blocking agents or monoamino oxidase inhibitors, excluded patients from the study.
The study protocol was approved by the institutional Ethics Committees according to Portuguese law and all patients gave written informed consent for participation. A total of 20 consecutive patients were to be recruited as previously agreed with the study sponsor.
PBPC mobilization
Patients were treated with 20 mg/kg/day of ancestim in combination with 10 mg/kg/day of filgrastim, by separate subcutaneous injection, for mobilization of PBPC. A minimum of 14 days was required between the first PBPC collection attempt and the beginning of ancestim plus filgrastim administration. In Lisboa, where LVL was performed, patients received both cytokines once daily for 6 consecutive days and leukapheresis was performed on day 6. If a suboptimal PBPC product was collected on day 6, a further LVL session was planned for day 7. In Porto, where patients underwent SVL, cytokines were administered until the last day of leukapheresis, which started on day 5 of cytokine administration. All patients received prophylactic ranitidine 300 mg/day and cetirizine 10 mg/day orally, from 24 h before mobilization until 48 h after the last administration of cytokines. They also received salbutamol two puffs 30-60 min before each injection of ancestim.
The concentration of CD34 þ cells in the peripheral blood was measured before starting the mobilization with ancestim and filgrastim (day 1), on the day 5 of mobilization and in each day of leukapheresis (up to day 7), before starting the procedure. In all patients, the concentration of CD34 þ cells in the peripheral blood had also been measured on the day of the first leukapheresis performed during the 'pre-study' mobilization.
The PBPC content of all leukaphereses products was expressed as CD34 þ cells/kg of body weight. Since, in patients who underwent SVL, the number of leukaphereses performed per patient and the number of processed BVs per leukapheresis session differed between the 'pre-study' suboptimal mobilization attempt and the ancestim plus filgrastim, 'on-study' mobilization, we compared the 'prestudy' with the 'on-study' number of CD34 þ cells collected per unit of BV processed in patients undergoing either LVL or SVL, expressed as CD34/kg/BV. Thus, each patient was used as his own control.
To evaluate the success of the ancestim-filgrastim PBPC mobilization, the fold increase in the peripheral blood CD34
þ cell concentration between day 1 (before starting mobilization) and day 5 of mobilization was measured. The concentration of CD34 þ cells in peripheral blood on the day of first leukapheresis after mobilization with ancestim and filgrastim and after the previous suboptimal mobilization was compared in a pairwise way.
Similarly, the number of CD34 þ cells collected after mobilization with ancestim and filgrastim was compared pairwise with the number of CD34 þ cells collected after the 'pre-study' suboptimal mobilization, adjusted for body weight and number of BVs processed.
Large volume leukapheresis
LVL were performed using the mononuclear cell collection procedure (version 3.6) of the COBE Spectra Cell Separator (COBE Laboratories, Lakewood, CO, USA) as previously described. 10 Briefly, a combination of sodium citrate (ACD-A -Bruneau Laboratories, France) and preservative-free heparin anticoagulation was used, with heparin added to one or more bags of ACD-A, depending on the platelet count at the beginning of the procedure. The whole blood to anticoagulant ratio was rapidly increased to 50:1 to allow a target blood flow rate of 150 ml/min. The target number of BVs processed was identical to the number of BVs processed on the 'pre-study' LVL that followed the suboptimal previous PBPC mobilization attempt. A continuous intravenous infusion of an electrolyte solution containing calcium chloride (as well as magnesium sulfate and potassium chloride) was administered during LVL, through the return apheresis line, to neutralize the hypocalcemic effect of citrate. Serial measurements of ionized calcium were performed.
In patients not achieving the target of 2.5 Â 10 6 CD34 þ / kg cells in the PBPC product collected on day 6, a second LVL was planned for the following day (day 7). Such procedure was dependent on the concentration of peripheral blood CD34 þ cells and on platelet counts in the morning of day 7.
Standard volume leukapheresis
SVL were performed in the COBE Spectra, according to the manufacturer's protocol. ACD-A and heparin were used for anticoagulation and the blood flow rate was adjusted to the catheter output and patient tolerance. The procedure was stopped after processing up to 4 BVs or sooner, depending on patient tolerance. Peripheral veins and/or central venous catheters were used as vascular access. Measurements of ionized calcium were routinely taken and electrolyte solutions were administered when clinically indicated.
Approximately 2 Â 10 6 cells obtained from peripheral blood or leukapheresis product samples were incubated with 10 ml of phycoerythrin-conjugated HPCA2 mouse monoclonal anti-CD34 antibody (Becton-Dickinson, San Jose, CA, USA) and 10 ml fluorescein-conjugated mouse monoclonal anti-CD45 antibody (Immunotech, Marseille, France), kept for 15 min in the dark at room temperature, lysed with Becton-Dickinson lysing solution (according to the manufacturer's instructions), washed in phosphatebuffered saline (PBS) and resuspended in 200 ml of PBS. Analysis was performed on a FACScan flow cytometer (Becton-Dickinson, San Jose, CA, USA) within 24 h of sample collection and results reported as a percentage of nucleated cells. The analysis was performed by sequential gating on CD45 þ events and then CD34 þ events, after excluding cellular debris. Estimates of peripheral blood CD34 þ cell content per microliter were made by applying the following formula:
Statistical analysis
The median and range of the number of CD34 þ cells/kg collected after ancestim plus filgrastim PBPC mobilization and on the 'pre-study' mobilization, as well as the median and range of CD34 þ cell concentration in the peripheral blood before mobilization and before and during harvesting were calculated.
Since each patient served as his own control, we compared the efficacy of mobilizations and of harvesting procedures by performing pairwise comparisons using the nonparametric sign-rank test, testing the null hypothesis of zero difference between 'pre-study' and 'on-study' PBPC mobilization and collection procedures. The level of statistical significance was set at po0.05.
Results
Patients were included between January 2000 and November 2001. During the study period, 85 adult patients with cancer other than leukemia, and without prior high-dose therapy with stem cell support, underwent LVL for PBPC collection in Lisboa and were eligible if o2. 
CD34
þ cells/kg and were considered to be 'poor mobilizers' and thus study candidates. From those, four were not screened, three refused to participate, three had a positive allergy history precluding the use of ancestim plus filgrastim, one underwent a second mobilization with chemotherapy that was planned immediately after the first suboptimal mobilization, one progressed before the second mobilization and nine were included in the study. One of these nine patients had disease progression before starting ancestim and filgrastim administration and was removed from the study, leaving eight patients included.
A total of 52 adult patients with cancer other than leukemia and without prior high-dose therapy underwent SVL for PBPC harvesting during the study period in Porto. These included 10 patients with Hodgkin's disease, 20 with non-Hodgkin's lymphoma, 17 with multiple myeloma, three with germ cell tumor and two with Ewing's sarcoma. Two patients were mobilized and harvested twice because of a first insufficient product. A median of 3.14 Â 10 6
þ cells/kg (range 0.15-14.5) were collected from these patients. Of the 52 patients, 18 (35%), including the two who were mobilized twice, had PBPC harvests with less than 2.5 Â 10 6 CD34 þ cells/kg. Of these 18 patients, 12 were included.
Thus, a total of 20 patients participated in the study. The median time between the last 'pre-study' leukapheresis and the beginning of ancestim plus filgrastim mobilization was 29 days (range 14-148). In Lisboa, the eight patients underwent LVL after ancestim plus filgrastim mobilization, with a target number of BVs to be processed equal to the one processed in the 'pre-study' mobilization. In three patients, a second LVL was performed 24 later, as planned, aiming to collect at least 2.5 Â 10 6 CD34 þ cells/kg for transplantation. Reasons for not performing the second LVL in the remaining five patients included the harvesting of an adequate product on the first LVL (day 6) in two patients and a very low concentration of peripheral blood CD34 þ cells (1-2.3/ml) and/or platelet counts less than 50 000/ml in the morning of day 7 in the other three cases. In Porto, 12 patients underwent a median of 3 (range 2-3) SVL after mobilization with ancestim plus filgrastim. The characteristics of the patients undergoing LVL and SVL are shown in Table 1 . There were seven women and 13 men, with a median age of 47 (20-66) years old. Hematological malignancies predominated, with 12 patients with nonHodgkin's lymphoma, three with multiple myeloma and two with Hodgkin's disease; two patients had germ cell tumors and one had Ewing's sarcoma. Most patients (80%) received G-CSF alone as their first mobilization attempt. Half of the patients had received a minimum of 10 cycles of chemotherapy prior to inclusion in the study.
Mobilization efficacy
The details of the LVL and SVL procedures performed in each patient entering the study are described in Table 2a (LVL) and b (SVL). The median number of BVs processed was 7.87 (range 3.16-10.91) for LVL (day 6-only LVL) and 11.97 (range 6.93-13.15) for SVL (all SVL combined), respectively.
The number of leukaphereses performed after the 'prestudy' PBPC mobilization and after ancestim plus filgrastim mobilization was not the same in eight patients. Three patients underwent two consecutive LVL after ancestim plus filgrastim treatment in the hope of obtaining an adequate product for transplant; thus, in those patients (numbers 2, 5 and 6) a higher number of BVs volumes were processed following 'on-study' mobilization as compared to the previous mobilization.
The peripheral blood concentration of CD34 þ cells on the day of the first leukapheresis performed after ancestim plus filgrastim mobilization was compared with the peripheral blood concentration of CD34 þ cells on the day of the first leukapheresis of the 'pre-study' mobilization. For patients undergoing LVL the median number of CD34 þ cells/ml was 2.61 (range 1.15-28.56) and 2.59 (range 1.86-15.14), respectively. Similarly, for patients submitted to SVL the median number of CD34 þ cells/ml was 5 (range While in four patients the 'pre-study' mobilization regimen was an association of chemotherapy and hematopoietic growth factor, in the remaining 16 patients it was attempted with filgrastim alone (10 mg/kg/day in 15 patients, 16 mg/kg/day in one patient). To determine the influence of the addition of ancestim to the filgrastim mobilization regimen, we compared in this homogeneous subgroup the peripheral blood concentration of CD34 þ cells on the day of the first 'on-study' leukapheresis with that of the first 'pre-study' leukapheresis. This comparison should elucidate if ancestim has an additive and/or synergistic effect on filgrastim mobilization of hematopoietic progenitors in 'poor mobilizers'. Such analysis showed no difference between the two cycles of PBPC mobilization, with 11 of 16 patients having lower peripheral blood concentration of CD34 þ cells on the day of the first leukapheresis after the ancestim plus filgrastim mobilization than after filgrastim-only mobilization (p ¼ 1).
The PBPC mobilizing effect of ancestim plus filgrastim was documented by comparing the concentration of CD34 þ cells in peripheral blood on day 5 and on day 1 of treatment (before cytokine administration). Day 5 was chosen because patients who underwent SVL started the collections on that day. For the 14 patients with CD34 þ cell counts determined on both time points, the median fold increase of peripheral blood CD34 þ cell concentration during mobilization was 5.4 (varying from 1 to 29).
Published data suggest that after filgrastim plus ancestim administration, the peripheral blood concentration of CD34 þ cells is maximal on day 6 of treatment. 19 Therefore, this time point was chosen for PBPC collection in patients undergoing LVL. To further investigate this matter, the peripheral blood CD34 þ cell concentration was measured on days 5, 6 and 7 of ancestim plus filgrastim mobilization. In patients undergoing LVL, the peripheral blood CD34 þ cell concentration peaked on day 5 in five patients and on day 6 in three. Similarly, in patients undergoing SVL the peripheral blood CD34 þ cell concentration peaked on day 5 in six patients, on day 6 in four and on day 7 in one; in the remaining patients, the CD34 þ cell concentration was the same in both days of collection. However, in patients undergoing SVL, who started harvesting on day 5, the CD34 þ cell depleting effect of leukapheresis may have influenced the peripheral blood CD34 þ cell concentrations on days 6 and 7.
The group in Lisboa and others have previously reported the CD34 þ cell depleting effect of LVL. 10, 14, 26 Still, we were concerned that a second LVL, performed 24 h after the first, might allow the collection of a PBPC with adequate CD34 þ cells numbers for transplantation. However, the peripheral blood CD34 þ cell concentration on day 7 was below 2.5/ml in all patients (data not shown). As documented in this study, in our hands the probability of collecting a PBPC product with at least 2 Â 10 6 CD34 þ cells/kg is very low in patients with less than 4.5 CD34
þ cells/ml in the peripheral blood at the beginning of LVL. 10 In fact, none of the three patients undergoing a second LVL on day 7 obtained a PBPC with more CD34 þ cells/kg than the one collected on day 6 nor were they able to provide an overall product with enough progenitors to allow proceeding to transplantation.
PBPC collection efficacy
The median number of CD34 þ cells/kg harvested after mobilization with ancestim plus filgrastim was 1.29 (range 0.1-3.81), compared to a median of 0.87 (0.09-2.17) after the 'pre-study' mobilization attempt (p ¼ 0.82) ( Table 2 ). The median number of CD34 þ cells/kg collected in patients who underwent LVL and SVL after ancestim plus filgrastim mobilization was 0.55 Â 10 6 (range 0.1-3.81) and 1.29 Â 10 6 (range 0.1-3.07), respectively. In the three patients who underwent LVL on days 6 and 7 of ancestim plus filgrastim mobilization, the number of CD34 þ cells/kg collected in both PBPC mobilization attempts was higher than 5 Â 10 6 /kg in one patient and higher than 2 Â 10 6 /kg in nine patients, respectively. Although each patient was analyzed as his own control, the number of BVs processed in the 'pre-study' leukaphereses was different from the number of BVs processed after ancestim plus filgrastim mobilization in many patients. To adjust for this imbalance, the number of CD34 þ cells/kg harvested per unit of BV processed was calculated in the 'pre-study' as well as 'on-study' PBPC collections. There was no difference between the median numbers of CD34 (Figure 1 ). For this analysis, in the subgroup of patients undergoing LVL only the day 6 PBPC product was considered, since an attempt was made to process the same number of BVs on day 6 of ancestim plus filgrastim mobilization as in the pre-study LVL.
In all, 12 (60%) patients underwent high-dose chemotherapy with stem cell support. Six patients were not transplanted because of an insufficient product, one because of disease progression and another one because of lack of indication for an immediate transplantation. In 11 patients, stem cell support was provided by the combined 'pre-study' and 'on-study' PBPC product; the remaining patient also received bone marrow support with 0.83 Â 10 6 CD34 þ cells/kg. All patients experienced hematopoietic recovery, reaching 500 neutrophils/ml a median of 11 days after transplantation (range þ 10 to þ 20), 1000 leukocytes/ml on day þ 12 ( þ 10 to þ 20) and 20 000 platelets/ml on day þ 14 ( þ 8 to þ 86). There was no clear relationship between CD34 þ cell dose and hematopoietic recovery, although the only patient with platelet recovery beyond day þ 22 was the patient who received the worst PBPC product (1.63 Â 10 6 CD34 þ cell/kg).
Toxicity
No clinically significant systemic toxicities were observed after ancestim plus filgrastim administration. Specifically, there were no anaphylactic reactions, bronchospasm or other severe hypersensitivity reactions. The only allergic reaction commonly observed was injection-site cutaneous erythema, sometimes with accompanying pruritus, that was present in 10 patients, and was always mild and reversible at the end of cytokine administration. Fever occurred in two patients, in one thought to be related to filgrastim administration. Facial flush and warmth was described by one patient and maleolar edema occurred in another; both effects were considered ancestim related. Two patients had nausea and one had nasal obstruction that were apparently independent from cytokine treatment. Three patients referred bone pain and myalgia thought to be related to filgrastim injection. One episode of mild, transient chest pain that resolved without treatment was described by one patient, and was not thought to be related to the cytokine administration. Two patients had central venous catheter infections that resulted in sepsis in one case (occurring 13 days after leukapheresis and termination of cytokine administration), requiring hospitalization and treatment with intravenous antibiotics. There were no toxic deaths and no patients were withdrawn from the study because of adverse reactions.
Discussion
Ancestim, recombinant human stem cell factor, has been reported to mobilize hematopoietic progenitors into the peripheral blood and several randomized clinical trials demonstrated its synergism with filgrastim. [29] [30] [31] The combination of ancestim and filgrastim increases the number of CD34 þ cells harvested and reduces the number of leukaphereses required to obtain a PBPC product adequate for transplantation. However, the majority of cancer patients who are candidates for high-dose therapy with /kg collected after the 'pre-study' mobilization and after administration of ancestim plus filgrastim, adjusted for the number of BVs processed in each mobilization attempt, is shown. stem cell support mobilize enough progenitors to ensure the collection of a PBPC product that is capable of rapid hematological recovery, when the mobilization is attempted with G-CSF alone or in combination with chemotherapy. Furthermore, ancestim administration is limited by a 3-10% rate of serious allergic reactions. 29 Thus, the maximal usefulness of the synergistic PBPC mobilization regimen of ancestim plus filgrastim would be in the subgroup of up to a third of autologous transplantation candidates who are unable to mobilize and collect enough progenitors with standard chemotherapy and/or growth factor treatment.
The aim of the present study was to evaluate the efficacy of the combined administration of ancestim and filgrastim in patients who did not mobilize enough PBPC for transplantation with a previous standard mobilization regimen. We mobilized with ancestim plus filgrastim 20 cancer patients who were 'poor PBPC mobilizers', defined as having a previous PBPC mobilization attempt with less than 2.5 Â 10 6 CD34 þ cells/kg in the overall product. Stiff et al 31 reported that in heavily pre-treated Hodgkin's and non-Hodgkin's lymphoma patients, the simultaneous administration of ancestim plus filgrastim increases the median yield of CD34 þ cells collected per leukapheresis and reduced the number of leukaphereses required to collect a target of 5 Â 10 6 CD34 þ cells/kg. Although such patients were potential 'poor PBPC mobilizers' because of prior therapy, the inability to mobilize and collect PBPC with standard approaches before study entry was not documented. In another study, To et al 27 added ancestim to the mobilizing regimen administered to patients who had collected between 0.5 and 1.9 Â 10 6 /kg CD34 þ cells in a previous mobilization attempt using filgrastim, with or without chemotherapy. In contrast to our study, for the 13 patients initially mobilized with filgrastim and later remobilized with ancestim plus filgrastim, ancestim was started 3 days before filgrastim. The authors reported a statistically significant three-fold increase in the median number of CD34 þ cells/kg collected in the second mobilization attempt. However, we do not know whether the same number of BVs were processed in each mobilization course. Whether these results differ from ours due to the schedule of growth factor administration or because, in our series, five of 20 patients had less than 0.5 Â 10 6 CD34 þ cells/kg in the pre-study collection, is unknown. In fact, in five of 15 patients with a 'pre-study' PBPC product with at least 0.5 Â 10 6 CD34 þ cells/kg, more than 2 Â 10 6 CD34 þ cells/kg were collected with ancestim plus filgrastim, in contrast to none of five patients with an initial product with less than 0.5 Â 10 6 CD34 þ cells/kg. Despite being a small nonrandomized phase II study, the use of each patient as his own control decreased random variation between patients and increased coherence of pairwise comparisons. Furthermore, for patients undergoing LVL, the same number of BVs was processed during the single 'on-study' and the single 'pre-study' collection attempts. For patients undergoing SVL, to adjust for differences in the number of leukaphereses performed and in the total BV processed in the 'pre-study' and 'on-study' mobilization attempts, the number of CD34 þ cells/kg collected per unit of BV processed were used in pairwise comparisons.
Patients were eligible if they had a previous PBPC collection with less than 2.5 Â 10 6 CD34 þ cells/kg. We 26 and others 24 have shown that there is a direct relationship between the number of CD34 þ cells reinfused and hematological recovery. While 2 Â 10 6 CD34 þ cells/kg are enough to ensure a rapid neutrophil recovery, a minimum of 5 Â 10 6 CD34 þ cells/kg are required for optimal platelet recovery. 24, 26 Thus, we chose the eligibility cut-off of 2.5 Â 10 6 CD34 þ cells/kg aiming to collect an ideal overall product with 5 Â 10 6 CD34 þ cells/kg after the second 'onstudy' mobilization attempt.
Different from results obtained in unselected patient populations, 19 in the group of 'poor PBPC mobilizers' included in this study, we did not observe an increase in the concentration of peripheral blood CD34 þ cells on the day of the first collection when mobilized with ancestim plus filgrastim, compared to filgrastim alone. In fact, the majority (11 out of 16) of patients previously mobilized with filgrastim alone had lower peripheral blood concentration of CD34 þ cells on the day of the first leukapheresis after ancestim plus filgrastim administration than after filgrastim-only mobilization. Neither was there an increase in the number of collected CD34 þ cells/kg per unit of BV processed after mobilization with ancestim plus filgrastim (0.09 Â 10 6 , ranging from 0.03 to 0.28) compared to the 'pre-study' suboptimal mobilization (0.1 Â 10 6 , ranging from 0.01 to 0.49). Furthermore, after two PBPC mobilization and collection attempts more than half of patients (11 out of 20) still had an overall PBPC product with less than 2 Â 10 6 CD34 þ cells/kg. In four patients, the PBPC product collected after mobilization with ancestim plus filgrastim had more than 2.5 Â 10 6 CD34 þ cells/kg. Interestingly, three of these four patients had the highest number of collected CD34 þ cells/kg after the pre-study suboptimal mobilization attempt (two LVL patients, one SVL patient), suggesting they were the least 'poor PBPC mobilizers' in this cohort.
Several factors could have contributed to the unfavorable results observed in this study. Firstly, the dosage of growth factor administered might not be the ideal to obtain the synergism between ancestim and filgrastim. However, it has been shown that 10 mg/kg/day of filgrastim is more efficacious than 5 mg/kg/day in the mobilization of CD34 þ hematopoietic progenitors 21 and that this dose synergizes with 20 mg/kg/day of ancestim for the mobilization of PBPC. 29 On the other hand, doses of ancestim higher than 20 mg/kg/day can induce allergic reactions and are not recommended for PBPC mobilization. Secondly, the ideal timing for PBPC collection after ancestim plus filgrastim administration could have been missed. However, SVL were always started on day 5 and continued up to day 7, following a standard approach; serial measurements of peripheral blood CD34 þ cell concentration on days 5, 6 and 7 of treatment support this strategy. Regarding LVL, a single collection on day 6 of treatment was based on our own observations with filgrastim-alone PBPC mobilization 10 and on previous data suggesting that CD34 þ cell concentration peaks in the peripheral blood on day 6 of ancestim plus filgrastim administration. 19 In LVL patients, we documented that the CD34 þ cell concentration peaked on day 5 in five patients and on day 6 in three. However, among the five patients with a maximum peripheral blood CD34 þ cell concentration on day 5, the absolute difference between days 5 and 6 of mobilization varied only between 0.23 and 3.79 CD34 þ cells/ml. Analysis of CD34 þ cell concentration on day 7 is limited by the depleting effect of the leukapheresis performed on day 6.
In conclusion, we found no evidence that the combined administration of ancestim plus filgrastim in the doses and schedules used in this study were able to overcome the difficulty in collecting a PBPC product capable of allowing rapid and sustained hematopoietic recovery in patients previously shown to be 'poor PBPC mobilizers'. c-kit) administered in vivo to mice either alone or in combination with G-CSF. 
